Novel composition for treatment of essential thrombocythemia
AssigneeAop Orphan Pharmaceuticals AG
InventorsRudolf WIDMANN, Georg STRIEDER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia.
Claims19
A pharmaceutical composition free of gastric coating comprising anagrelide HCl, a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid, wherein the non-pH dependent polymer is selected from the group consisting of a polyacrylacid, a cellulose derivative, and a polyacrylamide, and wherein the amount of the non-pH dependent polymer is between 1.5 and 2.5 fold of the anagrelide (w/w).
A method of treating essential thrombocythemia, comprising administering to a patient in need thereof a pharmaceutical composition free of any gastric coating, the composition comprising anagrelide HCl, a non-pH dependent polymer, and a pharmaceutically acceptable water soluble acid, wherein the non-pH dependent polymer is selected from the group consisting of a polyacrylacid, a cellulose derivative, and a polyacrylamide, and wherein the amount of the non-pH dependent polymer is between 1.5 and 2.5 fold of the anagrelide (w/w).
Dependencies are inferred from the claim text.